Loading patent…
AssigneeProclara Biosciences, Inc.
InventorsRichard A. Fisher, Robert George Edward Holgate, Francis Joseph Carr, Timothy David Jones
Estimating the term…
The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
A polypeptide comprising a variant of a starting amino acid sequence, wherein the starting amino acid sequence is selected from the group consisting of:
A polypeptide variant comprising a modified starting sequence, wherein the starting sequence is selected from SEQ ID NO:3 or SEQ ID NO:7 and the modification is two or three amino acid substitutions, the polypeptide being selected from any one of the polypeptides set forth below:
Dependencies are inferred from the claim text.